Skip to content

Evaluation of the effect of Tui Na in Chinese medicine and innovation of the inheritance of treatment model - Research on the biological effect mechanism of Tui Na intervention in chronic fatigue syndrome

Evaluation of the effect of Tui Na in Chinese medicine and innovation of the inheritance of treatment model - Research on the biological effect mechanism of Tui Na intervention in chronic fatigue syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005373
Enrollment
Unknown
Registered
2021-12-04
Start date
2022-02-28
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic fatigue syndrome

Interventions

Gongfa:Gongfa
Health control :No
Gongfa+Tuina:Gongfa+Tuina
chronic fatigue syndrome:No

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria of subjects with CFS: 1. Consistent with the CFS diagnostic consensus (developed by the CDC in 1994): (1) persistent or recurrent fatigue lasting more than 6 months; (2) exclusion of all organic diseases causing chronic fatigue based on history, physical signs or laboratory findings. (2) and at least four of the following eight items at the same time: (1) short-term memory loss or inability to concentrate; (2) sore throat; (3) lymph node pain; (4) muscle aches and pains; (5) joint pain without redness or swelling; (6) new headache; (7) inability to recover energy after sleep; (8) discomfort for 24 consecutive hours after physical or mental work; 2. Age = 20 and = 65 years, regardless of gender; 3. Not having received any other treatment within the last 1 month 3. not received any other treatment regimen that may affect the outcome; 4. voluntarily participated in this study and signed the informed consent form. The inclusion criteria of subjects without CFS: 1. did not meet the consensus of CFS diagnosis; 2. there was no mental illness; 3. the age was = 20 years old and = 65 years old, regardless of gender; 4. those who did not accept other treatment schemes that might affect the outcome within one month; 5. those who voluntarily participated in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria for subjects with CFS: Subjects will not be enrolled if they meet any of the following criteria: 1. fatigue symptoms can be relieved with rest; 2. fatigue symptoms do not cause a substantial decrease in the ability to work, receive education, social activities, recreational activities and personal life; 3. illnesses that can clearly cause fatigue such as tumours, diabetes, rheumatic immune disease, etc.; 4. chronic illness; 5. psychiatric illness; 6. pregnant and Lactating women; 7. Those who have participated in other clinical trials within 1 month or are participating in other clinical trials; 8. Those who are not suitable for MRI, such as those with pacemakers, nerve stimulators, metallic foreign bodies (metal implants, contraceptive rings) in the body, insulin pumps, etc. Exclusion criteria for subjects without CFS: 1. Suffering from chronic diseases; 2. Pregnant and lactating women; those who have participated in other clinical trials or are participating in other clinical trials within 3.1 months; 4. Those who are not suitable for MRI examination, such as those with pacemakers, nerve stimulators, metal foreign bodies (metal implants, contraceptive rings), insulin pumps, etc.

Design outcomes

Primary

MeasureTime frame
Child Fatigue Scale;

Secondary

MeasureTime frame
Joint motion angle;Blood lactic acid;Blood oxygen concentration;Joint moment;Surface electromyography;gamma interferon;Brief profile of Mood States;Pittsburgh Sleep Quality Index;Blood immunoglobulin;transforming growth factor-ß;Quality of life scale;fMRI;Isokinetic muscle strength test;Tumor necrosis factor-a;Muscle condition rapid measurement system;Blood cortisol;Interleukin;C reactive protein;

Countries

China

Contacts

Public ContactMin Fang
fm-tn0510@shutcm.edu.cn+86 18930658005

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026